Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker (Nasdaq: BRKR) has announced a public offering of 6,000,000 shares of its common stock. The company may offer an additional 900,000 shares within 30 days based on the underwriters' decision.
The offering, managed by BofA Securities and J.P. Morgan, aims to reduce Bruker's indebtedness following recent acquisitions, specifically repaying part of its borrowings under a revolving credit agreement dated January 18, 2024.
The offering is contingent on market conditions and other customary closing requirements, with no guarantee on its completion or terms. A registration statement has been filed with the SEC and the final prospectus will be available once filed.
Bruker (Nasdaq: BRKR) will host an Investor Webinar on May 17, 2024, from 10 am to 12 noon EDT. The webinar will cover Bruker’s three recent acquisitions: Chemspeed, ELITech, and the NanoString business. Presentations will be given by CEO Frank H. Laukien, CFO Gerald Herman, and leaders of the new acquisitions. A medium-term financial outlook update will also be provided. The event will include a live Q&A session for analysts and investors. Webinar access details will be available on Bruker’s Investor Relations website, with a replay available post-event.
Bruker (Nasdaq: BRKR) has announced that its Board of Directors has approved a quarterly cash dividend of $0.05 per share.
The dividend will be paid on June 17, 2024, to stockholders who are on record as of June 3, 2024.
Bruker (Nasdaq: BRKR) will host an Investor Webinar on May 17, 2024, to discuss recent acquisitions and provide a financial outlook. The webinar will feature presentations by company executives and leaders of the acquired businesses.
Bruker announced that the German Federal Patent Court ruled in favor of NanoString Technologies Germany GmbH by invalidating a patent asserted by 10x Genomics in Germany. This legal win allows NanoString, now a Bruker business, to seek an end to the injunction impacting sales of CosMx SMI products in Germany. The ruling is a significant victory for NanoString and Bruker, enabling a re-leveling of the playing field in the research tools industry in Germany.
Bruker has completed the acquisition of NanoString Technologies, Inc., for approximately $392.6 million, acquiring assets such as nCounter®, GeoMx®, CosMx™, and AtoMx™ product lines. The acquisition aims to enhance gene expression analysis and spatial transcriptomics for research purposes. NanoString generated revenues of $168 million in 2023 and has been important in supporting discovery, translational, and pre-clinical disease research with over 7,000 publications.
Bruker has completed the acquisition of ELITechGroup for €870 million in cash, excluding the clinical chemistry business, becoming a leading infectious disease specialist in the in-vitro diagnostics market. ELITech offers innovative sample-to-answer systems and assays for molecular diagnostics, with FY 2023 revenue of approximately EUR 150 million.
Bruker (BRKR) reported strong Q1 2024 financial results with revenues of $721.7 million, up 5.3% yoy. GAAP EPS was $0.35, non-GAAP EPS $0.53. FY 2024 guidance raised to $3.29-$3.35 billion, implying 11%-13% yoy growth. Acquisition of ELITech expected to boost revenue and EPS.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
